Emergent BioSolutions (NYSE:EBS) Lowered to "Hold" Rating by StockNews.com

Emergent BioSolutions (NYSE:EBS - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Wednesday.

Other research analysts have also recently issued reports about the company. Benchmark lifted their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a report on Thursday, November 7th. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Emergent BioSolutions in a report on Tuesday, March 4th.

Emergent BioSolutions Price Performance

Shares of NYSE EBS traded down $0.08 during midday trading on Wednesday, reaching $5.77. 936,078 shares of the company traded hands, compared to its average volume of 2,647,240. The firm has a market cap of $313.25 million, a PE ratio of -1.41 and a beta of 1.80. The stock's 50-day simple moving average is $9.33 and its 200-day simple moving average is $8.95. Emergent BioSolutions has a 12 month low of $1.82 and a 12 month high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Remove Ads

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The business had revenue of $194.70 million during the quarter, compared to analysts' expectations of $254.67 million. During the same period in the previous year, the business posted ($0.77) earnings per share. As a group, equities analysts anticipate that Emergent BioSolutions will post -0.63 earnings per share for the current fiscal year.

Institutional Trading of Emergent BioSolutions

Several institutional investors and hedge funds have recently added to or reduced their stakes in EBS. Aegis Wealth Management LLC acquired a new position in shares of Emergent BioSolutions during the 4th quarter worth about $145,000. B. Riley Wealth Advisors Inc. grew its position in shares of Emergent BioSolutions by 21.9% during the 4th quarter. B. Riley Wealth Advisors Inc. now owns 41,800 shares of the biopharmaceutical company's stock worth $400,000 after buying an additional 7,500 shares during the period. Alpine Global Management LLC acquired a new position in shares of Emergent BioSolutions during the 4th quarter worth about $112,000. Two Sigma Advisers LP grew its position in shares of Emergent BioSolutions by 14.1% during the 4th quarter. Two Sigma Advisers LP now owns 656,500 shares of the biopharmaceutical company's stock worth $6,276,000 after buying an additional 81,000 shares during the period. Finally, Two Sigma Investments LP grew its position in shares of Emergent BioSolutions by 13.9% during the 4th quarter. Two Sigma Investments LP now owns 846,766 shares of the biopharmaceutical company's stock worth $8,095,000 after buying an additional 103,574 shares during the period. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.